Subtopic Deep Dive
Hyperprolactinemia Management
Research Guide
What is Hyperprolactinemia Management?
Hyperprolactinemia management involves dopamine agonist therapy, surgical interventions for prolactinomas, and strategies to address cabergoline resistance using evidence-based guidelines.
Dopamine agonists like cabergoline normalize prolactin levels in most patients with prolactinomas (Melmed et al., 2011, 1753 citations). Surgical options apply when medical therapy fails, with neuroimaging guiding decisions (Gillam et al., 2006, 820 citations). Over 455 patients showed cabergoline efficacy with good tolerability (Verhelst et al., 1999, 443 citations).
Why It Matters
Hyperprolactinemia management restores gonadal function, improves fertility, and prevents osteopenia in patients with prolactinomas, which comprise 40% of pituitary adenomas (Gillam et al., 2006). Cabergoline reduces tumor size and prolactin levels effectively, minimizing surgery needs (Verhelst et al., 1999; Bevan et al., 1992). Guidelines from Melmed et al. (2011) standardize diagnosis and treatment, reducing medication intolerance and tumor recurrence risks across endocrine practice.
Key Research Challenges
Cabergoline Resistance Mechanisms
Some patients fail to respond to cabergoline due to D2 receptor mutations or tumor biology factors (Gillam et al., 2006). Management shifts to surgery or alternative agonists, complicating long-term control (Melmed et al., 2011). Verhelst et al. (1999) noted resistance in a subset of 455 patients.
Long-term Tumor Recurrence
Prolactinomas recur after dopamine agonist withdrawal, requiring lifelong monitoring (Bevan et al., 1992). Neuroimaging protocols track progression, but risks persist post-surgery (Gillam et al., 2006). Melmed et al. (2011) guidelines emphasize sustained therapy to prevent relapse.
Medication Intolerance Issues
Side effects like nausea limit dopamine agonist adherence, impacting fertility outcomes (Verhelst et al., 1999). Dose titration strategies help, but intolerance affects 10-20% of cases (Melmed et al., 2011). Balancing efficacy and tolerability remains critical.
Essential Papers
Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Шломо Мелмед, Felipe F. Casanueva, Andrew R. Hoffman et al. · 2011 · The Journal of Clinical Endocrinology & Metabolism · 1.8K citations
Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treat...
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
Annamaria Colao, Diego Ferone, Paolo Marzullo et al. · 2004 · Endocrine Reviews · 1.3K citations
This review focuses on the systemic complications of acromegaly. Mortality in this disease is increased mostly because of cardiovascular and respiratory diseases, although currently neoplastic comp...
High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liege, Belgium
Adrian Daly, Martine Rixhon, Christelle Adam‐Guillermin et al. · 2006 · The Journal of Clinical Endocrinology & Metabolism · 1.0K citations
Abstract Context: Prevalence data are important for assessing the burden of disease on the health care system; data on pituitary adenoma prevalence are very scarce. Objective: The objective of the ...
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Maria Fleseriu, Ibrahim A. Hashim, Niki Karavitaki et al. · 2016 · The Journal of Clinical Endocrinology & Metabolism · 886 citations
Using an evidence-based approach, this guideline addresses important clinical issues regarding the evaluation and management of hypopituitarism in adults, including appropriate biochemical assessme...
Advances in the Treatment of Prolactinomas
Mary P. Gillam, Mark E. Molitch, Gaetano Lombardi et al. · 2006 · Endocrine Reviews · 820 citations
Prolactinomas account for approximately 40% of all pituitary adenomas and are an important cause of hypogonadism and infertility. The ultimate goal of therapy for prolactinomas is restoration or ac...
Extrapituitary Prolactin: Distribution, Regulation, Functions, and Clinical Aspects*
Nira Ben‐Jonathan, John L. Mershon, Donald L. Allen et al. · 1996 · Endocrine Reviews · 719 citations
PRL affects more physiological processes than all other pituitary hormones combined. Among these are the regulation of mammary gland development, initiation and maintenance of lactation, immune mod...
Dopamine Agonists and Pituitary Tumor Shrinkage
John S. Bevan, Jonathan Webster, C. W. BURKE et al. · 1992 · Endocrine Reviews · 448 citations
The primary aim of this review has been to clarify the tumor shrinking effects of dopamine agonists on pituitary macroadenomas of different cell types. Shrinkage is most dramatic for macroprolactin...
Reading Guide
Foundational Papers
Start with Melmed et al. (2011, 1753 citations) for diagnosis-treatment guidelines; then Gillam et al. (2006, 820 citations) for prolactinoma therapy advances; Bevan et al. (1992, 448 citations) for dopamine agonist tumor effects.
Recent Advances
Verhelst et al. (1999, 443 citations) details cabergoline in 455 patients; Fleseriu et al. (2016, 886 citations) covers related hypopituitarism management.
Core Methods
Dopamine agonists (cabergoline titration, Verhelst et al. 1999); transsphenoidal surgery; serial MRI and prolactin assays (Melmed et al. 2011); resistance assessment via D2 receptor analysis (Gillam et al. 2006).
How PapersFlow Helps You Research Hyperprolactinemia Management
Discover & Search
Research Agent uses searchPapers and citationGraph to map dopamine agonist studies from Melmed et al. (2011, 1753 citations), revealing connections to Verhelst et al. (1999) on cabergoline in 455 patients. exaSearch finds recent resistance mechanisms; findSimilarPapers expands from Gillam et al. (2006).
Analyze & Verify
Analysis Agent applies readPaperContent to extract cabergoline dosing from Verhelst et al. (1999), then verifyResponse with CoVe checks guideline adherence against Melmed et al. (2011). runPythonAnalysis computes meta-analysis of tumor shrinkage rates from Bevan et al. (1992) using pandas, with GRADE grading for evidence strength on fertility outcomes.
Synthesize & Write
Synthesis Agent detects gaps in cabergoline resistance literature via contradiction flagging between Gillam et al. (2006) and Verhelst et al. (1999). Writing Agent uses latexEditText, latexSyncCitations for guideline summaries, and latexCompile for reports; exportMermaid visualizes treatment flowcharts from Melmed et al. (2011).
Use Cases
"Run meta-analysis on cabergoline tumor shrinkage rates across studies."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas aggregation of rates from Bevan et al. 1992 and Verhelst et al. 1999) → matplotlib plot of effect sizes.
"Draft LaTeX review on hyperprolactinemia guidelines with citations."
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Melmed et al. 2011) → latexCompile → PDF with prolactinoma treatment algorithm.
"Find code for prolactin level modeling in dopamine therapy simulations."
Research Agent → paperExtractUrls (Gillam et al. 2006) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for PRL dynamics.
Automated Workflows
Deep Research workflow scans 50+ papers on cabergoline resistance: searchPapers → citationGraph (Melmed et al. 2011 hub) → structured report with GRADE scores. DeepScan applies 7-step analysis to Verhelst et al. (1999): readPaperContent → CoVe verification → Python stats on 455-patient outcomes. Theorizer generates hypotheses on recurrence from Bevan et al. (1992) tumor shrinkage data.
Frequently Asked Questions
What defines hyperprolactinemia management?
It encompasses dopamine agonists like cabergoline as first-line therapy, surgery for resistance, and monitoring per Melmed et al. (2011) guidelines.
What are key methods in prolactinoma treatment?
Cabergoline normalizes prolactin in most cases (Verhelst et al., 1999); transsphenoidal surgery addresses macroadenomas (Gillam et al., 2006); MRI tracks response (Melmed et al., 2011).
What are pivotal papers?
Melmed et al. (2011, 1753 citations) provide Endocrine Society guidelines; Gillam et al. (2006, 820 citations) review prolactinoma advances; Verhelst et al. (1999, 443 citations) validate cabergoline in 455 patients.
What open problems exist?
Cabergoline resistance mechanisms need clarification (Gillam et al., 2006); long-term recurrence post-withdrawal persists (Bevan et al., 1992); fertility outcomes require optimized protocols (Melmed et al., 2011).
Research Pituitary Gland Disorders and Treatments with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Hyperprolactinemia Management with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.